Table 3.
Univariate and multivariate survival analyses in 191 patients with AFP-positive GC.
| Factor | Univariate P-value | Multivariate | ||
|---|---|---|---|---|
| HR | 95%CI | P-value | ||
| Sex (male vs. female) | 0.816 | |||
| Age (≤60 vs. >60 year) | 0.082 | |||
| ECOG-PS (score 0 vs. 1 vs. 2) | 0.944 | |||
| Tumor site (esophagogastric junction vs. gastric body/fundus vs. gastric antrum vs. leather stomach) | 0.615 | |||
| Gastrectomy (subtotal vs. total) | 0.232 | |||
| Tumor size (<3 vs. ≥3cm) | 0.043 | |||
| CEA (≤5 vs. >5 ng/ml) | 0.311 | |||
| CA19-9 (≤30 vs. >30 U/ml) | 0.362 | |||
| CA72-4 (≤6.9 vs. >6.9 U/ml) | 0.440 | |||
| Pathological differentiation (highly-moderately vs. poorly) | 0.031 | |||
| pT stage (T1 vs. T2 vs. T3 vs. T4) | 0.000 | 1.414 | 1.162–1.720 | 0.000 |
| pN stage (N0 vs N+) | 0.000 | 3.158 | 1.626–6.133 | 0.001 |
| Lauren type (intestinal vs. diffuse-mixed) | 0.001 | |||
| Venous invasion (yes vs. no) | 0.000 | 0.525 | 0.355–0.776 | 0.001 |
| Nerve invasion (yes vs. no) | 0.737 | |||
| Ki-67 (<50% vs. ≥50%) | 0.014 | |||
| Adjuvant chemotherapy (yes vs. no) | 0.122 | |||
| Serum AFP values (20–300 vs. 300–1,000 vs. >1,000 ng/ml) | 0.000 | 1.554 | 1.227–1.969 | 0.000 |
CI, confidence interval; HR, hazard ratio.